Cutaneous Squamous Cell Carcinoma

View All

World Pharma News
EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline

EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...

Find More

Cutaneous Squamous Cell Carcinoma Market & pipeline

Non-melanoma skin cancer is a group of cancers of the skin and is broadly classified into Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). It has the greatest prevalence in the United States, which can be seen through statistics which show that basal cell carcinoma accounts for 80% while Squamous cell c...

Find More